Dr. Biagio Ricciuti is Thoracic Oncologist at the Dana-Farber Cancer Institute. He authored more than 170 publications in international peer-reviewed journals including Nature, Nature Genetics, Nature Medicine, the Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, Annals of Oncology, and Clinical Cancer Research, among others. He is a recipient of the 2020 Young Investigator Award from the American Society of Clinical Oncology (ASCO), the 2020 Fellowship award from the International Association for the Society of Lung Cancer (IASLC), the 2021 Society for Immunotherapy of Cancer Young Investigator Award, the 2024 IASLC YIA. He is also a recipient of the 40 under 40 Emerging Leaders in Cancer Research. He is active member of the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), the International Association for Study of Lung Cancer (IASLC), American Association for Cancer Research (AACR), and the Society for Immunotherapy of Cancer (SITC). His clinical and translational research focus is on the genomic mechanism of response and resistance to PD-(L)1 blockade and targeted therapies in non-small cell lung cancer.